Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Vaverková

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Vnitrni Lekarstvi|March 1, 1996
[Lipid risk factors and their role in the pathogenesis of atherosclerosis]H Vaverková
Vnitrni Lekarstvi|June 21, 2007
[Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?]H Vaverková
Vnitrni Lekarstvi|May 1, 1995
[Hyperlipoproteinemia as a risk factor for ischemic heart disease. Epidemiologic and interventional studies]H Vaverková
Vnitrni Lekarstvi|May 10, 2001
[Dyslipoproteinemia and diabetes mellitus]H Vaverková
Casopis Lekaru Ceskych|March 14, 1975
[Hyperlipoproteinemias in internal medicine and therapeutic possibilities]M Kubasta, H Vaverková
Vnitrni Lekarstvi|September 1, 1995
[Lipoprotein (a): a genetic risk factor with atherogenic and thrombogenic properties]H Vaverková, D Novotný
Acta Universitatis Palackianae Olomucensis Facultatis Medicae|January 1, 1990
Effect of manganese ions on HDL2 precipitation with dextran sulfateN Skottová, J Bartek, H Vaverková
Vnitrni Lekarstvi|December 17, 2008
Relationship between familial combined hyperlipidemia and insulin resistanceD Jackuliaková, H Vaverková, D Karásek
Vnitrni Lekarstvi|May 10, 2001
[Dyslipoproteinemia and chronic kidney failure]J Zahálková, H Vaverková, V Kristof
Vnitrni Lekarstvi|April 1, 1996
[Personal experience with 200mg of micronized fenofibrate (Lipanthyl 200 M) in the treatment of primary dyslipidemias]H Vaverková, D Novotný, L Ficker
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Vnitrni Lekarstvi|March 1, 1996
[Lipid risk factors and their role in the pathogenesis of atherosclerosis]H Vaverková
Vnitrni Lekarstvi|June 21, 2007
[Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?]H Vaverková
Vnitrni Lekarstvi|May 1, 1995
[Hyperlipoproteinemia as a risk factor for ischemic heart disease. Epidemiologic and interventional studies]H Vaverková
Vnitrni Lekarstvi|May 10, 2001
[Dyslipoproteinemia and diabetes mellitus]H Vaverková
Casopis Lekaru Ceskych|March 14, 1975
[Hyperlipoproteinemias in internal medicine and therapeutic possibilities]M Kubasta, H Vaverková
Vnitrni Lekarstvi|September 1, 1995
[Lipoprotein (a): a genetic risk factor with atherogenic and thrombogenic properties]H Vaverková, D Novotný
Acta Universitatis Palackianae Olomucensis Facultatis Medicae|January 1, 1990
Effect of manganese ions on HDL2 precipitation with dextran sulfateN Skottová, J Bartek, H Vaverková
Vnitrni Lekarstvi|December 17, 2008
Relationship between familial combined hyperlipidemia and insulin resistanceD Jackuliaková, H Vaverková, D Karásek
Vnitrni Lekarstvi|May 10, 2001
[Dyslipoproteinemia and chronic kidney failure]J Zahálková, H Vaverková, V Kristof
Vnitrni Lekarstvi|April 1, 1996
[Personal experience with 200mg of micronized fenofibrate (Lipanthyl 200 M) in the treatment of primary dyslipidemias]H Vaverková, D Novotný, L Ficker
Pageof 6